Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS)

Authors

  • Beata Jagielska Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw
  • Andrzej Czubek Chamber of Commerce "Polish Medicine"
  • Konrad Talasiewicz Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw,
  • Adam Twarowski Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw
  • Piotr Rutkowski Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw
  • Maciej Krzakowski Maria Sklodowska-Curie Memorial Cancer Centre and the Institute of Oncology, Warsaw
  • Bianka Saetre Phoenix Biomolecular Engineering Foundation,
  • Marek Malecki 6Genomics Laboratories, Phoenix Biomolecular Engineering Foundation

Keywords:

breast cancer×trastuzumab×Herceptin×radiotherapy×chemotherapy×immunotherapy×hormonal therapy×adjuvant therapy×human epidermal growth factor receptor-2×estrogen receptor×progesterone receptor×overall survival×disease-free survival

Abstract

Abstract: In patients suffering from breast cancer, adjuvant radiation, chemotherapy, or immunotherapy, which immediately follow the surgery as the first line therapy, greatly improve overall (OS) and disease-free survival (DFS). Various regimens of adjuvant therapy for these patients have been tested contingent upon the clinical staging. Inclusion of adjuvant immunotherapy is particularly promising.

 

Downloads

Published

2023-03-27

How to Cite

Jagielska , B., Czubek, A., Talasiewicz , K., Twarowski , A., Rutkowski , P., Krzakowski , M., Saetre , B., & Malecki , M. (2023). Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS) . Molecular Cellular Therapy and Mechanism, 6(1), 37–49. Retrieved from https://journal.riverpublishers.com/index.php/MCTM/article/view/211

Issue

2018: Vol 6 Iss 1 2018

Section

Articles